Abstract: The invention provides a Probiotic microcapsule and a preparation method thereof, relating to the technical field of Probiotic products. The method includes the following steps: (a) preparing a capsule core containing Probiotics: mixing the capsule core materials including Probiotic powder, microcrystalline cellulose and starch, then adding a hydroxypropyl methylcellulose solution thereinto, while mixing evenly, making the obtained mixture materials into spherical particulate capsule cores by the extrusion spherization method; (b) coating by atomization: coating the microcapsule cores with a coating material solution in a single layer or multiple layers by atomization, getting core-shell microcapsules. The Probiotic microcapsules prepared by the present invention have a large encapsulation, uniform microcapsule particles, controllable particle size, storage-resistance, targetability to intestinal tracts, resistance to gastric acids and high temperature stability.

Abstract: A synthesis method of a targeted drug nCoVshRNA.2ACE2 of a COVID-19 virus, which includes the following steps: designing a consensus RNAi sequence siRNA of the COVID-19 virus and a variant strain thereof; synthesizing two complementary siRNAs into a small hairpin-shaped shRNA with a loop, and synthesizing ACE2 or a cell penetrating peptide ACE2 with a receptor-binding domain (RBD) as a ligand; and ligating the ACE2 to a sense strand and an antisense strand of the shRNA separately to synthesize the nCoVshRNA.2ACE2 including a shRNA region and an ACE2 region. The bivalent ACE2 functions to neutralize the RBD and deliver the shRNA in a targeted manner; an “shRNA-ACE2-RBD-virus” complex bridged by the ACE2 allows the shRNA to enter target cells with virus infection, thereby avoiding a side effect of non-specific delivery of the shRNA to uninfected cells, as well as resisting the variant strain and neutralizing the virus with the ACE2.

Abstract: The present invention provides a method for establishing a characteristic atlas of whole immune cells in lungs of mice with acute lung injury, including: extraction of the whole immune cells in lung; labeling of antibody with specific metal isotope for mass cytometry; staining the immune cells with the detection antibody; and mass cytometer analysis. The present invention is capable of isolating whole immune cells with high yield and viability on the basis of ensuring cell purity, greater than that of the conventional grinding method. The present invention binds stable metal isotopes to antibodies, while mass spectrometry flow channels are designed based on the principle of minimal channel interference to achieve a comprehensive description on the classification and function of whole immune cells in lung of the mouse with up to 43 markers simultaneously; dynamic alterations in the whole immune cells in lung of the mouse can also be observed.

Abstract: The present invention relates to the field of biotechnology and aims to provide a YAP1 gene-modified mesenchymal stem cell and a method for preparing the same. The mesenchymal stem cell is a primary mesenchymal stem cell modified by overexpressed YAP1 gene, wherein the YAP1 gene is derived from a YAP1 lentiviral vector or a YAP1 plasmid vector, and the primary mesenchymal stem cell is derived from any of the following human tissues: placenta, umbilical cord or adipose tissue. The YAP1 gene-modified mesenchymal stem cell obtained by the present invention has no effect on the phenotype and differentiation ability of MSCs themselves; the present invention can significantly promote the proliferation of mesenchymal stem cell and further increase the cell yield by modifying the mesenchymal stem cell with overexpressed YAP1 gene; therefore, a large number of mesenchymal stem cells can be rapidly obtained for clinical stem cell transplantation therapy.

Abstract: A method of treating fulminant hepatic failure in a subject, includes administering a therapeutically effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a DLL4 cytokine. A method of treating liver failure, sub-acute liver failure, chronic liver failure or acute-on-chronic liver failure in a subject, includes administering an therapeutically effective amount of a DLL4 cytokine to the subject.

Abstract: A method of treating fulminant hepatic failure in a subject, includes administering a therapeutically effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a DLL4 cytokine. A method of treating liver failure, sub-acute liver failure, chronic liver failure or acute-on-chronic liver failure in a subject, includes administering an therapeutically effective amount of a DLL4 cytokine to the subject.

Abstract: The present invention provides a hepatic lobule-like bioreactor. The bioreactor includes a nanofiber scaffold enclosed within a housing. An intrahepatic fibrous vascular network, a bile capillary network, upper hepatic bile ducts, lower hepatic bile ducts, a common bile duct connecting the upper and the lower hepatic bile ducts, and collagen fibrous microchannels for hepatocytes surrounded by the bile capillary network are distributed throughout the nanofiber scaffold. Bile capillaries in the bile capillary network are provided with two or more inlet ports for biliary epithelial cells. The collagen fibrous microchannels for hepatocytes are provided with two or more inlet ports for hepatocytes. The intrahepatic vascular network is provided with a liquid inlet port and a liquid outlet port. These ports extend through the housing.

Abstract: The present invention provides a hepatic lobule-like bioreactor. The bioreactor includes a nanofiber scaffold enclosed within a housing. An intrahepatic fibrous vascular network, a bile capillary network, upper hepatic bile ducts, lower hepatic bile ducts, a common bile duct connecting the upper and the lower hepatic bile ducts, and collagen fibrous microchannels for hepatocytes surrounded by the bile capillary network are distributed throughout the nanofiber scaffold. Bile capillaries in the bile capillary network are provided with two or more inlet ports for biliary epithelial cells. The collagen fibrous microchannels for hepatocytes are provided with two or more inlet ports for hepatocytes. The intrahepatic vascular network is provided with a liquid inlet port and a liquid outlet port.